Skip to content

Study · Not a test of the peptide alone · 2021

9 results

Safety and efficacy of Wharton's jelly-derived mesenchymal stem cells with teriparatide for osteoporotic vertebral fractures: A phase I/IIa study.

Shim J, Kim KT, Kim KG, Choi UY, Kyung JW, Sohn S, Lim SH, Choi H, Ahn TK, Choi HJ, Shin DE, Han I

Stem cells translational medicine16 Dec 2020Cited by 43 (Europe PMC)

PMID33326694 (opens in a new tab)PMCIDPMC7980202 (opens in a new tab)DOI10.1002/sctm.20-0308 (opens in a new tab)PepBankPUB-33326694
Read at sourcePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study9

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone9

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

  1. 01HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialActivity measurement

    In patients with osteoporotic vertebral fractures, osteocalcin levels did not differ significantly between combined WJ-MSCs-teriparatide treatment and teriparatide alone.

    In plain wordsIn patients with vertebral fractures, osteocalcin levels were similar with combined stem-cell-teriparatide treatment and teriparatide alone.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeOsteocalcin
    Study

    n = 14

    Comparator
    teriparatide alone
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    (c) the level of bone turnover markers were not significantly different between the two groups;
    2 context sentences
    Summary · context
    Fourteen subjects (teriparatide alone, n = 7; combined treatment, n = 7) completed follow-up assessment (visual analog scale [VAS], Oswestry Disability Index [ODI], Short Form-36 [SF-36], bone mineral density [BMD], bone turnover measured by osteocalcin and C-terminal telopeptide of type 1 collagen,…
    Summary · context
    We conducted a randomized, open-label, phase I/IIa study to determine the feasibility, safety, and effectiveness of Wharton's jelly-derived mesenchymal stem cells (WJ-MSCs) and teriparatide (parathyroid hormone 1-34) in OVCFs.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  2. 02HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome

    In patients with osteoporotic vertebral fractures, spine BMD T-scores increased in both groups without a significant difference between combination treatment and teriparatide alone.

    In plain wordsIn patients with osteoporotic vertebral fractures, spine bone density improved similarly with combined stem-cell-teriparatide treatment and teriparatide alone.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeSpine BMD T-score
    Study

    n = 14

    Comparator
    teriparatide alone
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    (d) BMD T-scores of spine and hip by DXA increased in both control and experimental groups without a statistical difference;
    1 context sentence
    Summary · context
    We conducted a randomized, open-label, phase I/IIa study to determine the feasibility, safety, and effectiveness of Wharton's jelly-derived mesenchymal stem cells (WJ-MSCs) and teriparatide (parathyroid hormone 1-34) in OVCFs.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  3. 03HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome

    In patients with osteoporotic vertebral fractures, hip BMD T-scores increased in both groups without a significant difference between combination treatment and teriparatide alone.

    In plain wordsIn patients with osteoporotic vertebral fractures, hip bone density improved similarly with combined stem-cell-teriparatide treatment and teriparatide alone.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeHip BMD T-score
    Study

    n = 14

    Comparator
    teriparatide alone
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    (d) BMD T-scores of spine and hip by DXA increased in both control and experimental groups without a statistical difference;
    1 context sentence
    Summary · context
    We conducted a randomized, open-label, phase I/IIa study to determine the feasibility, safety, and effectiveness of Wharton's jelly-derived mesenchymal stem cells (WJ-MSCs) and teriparatide (parathyroid hormone 1-34) in OVCFs.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  4. 04HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialActivity measurement

    In patients with osteoporotic vertebral fractures, C-terminal telopeptide levels did not differ significantly between combined WJ-MSCs-teriparatide treatment and teriparatide alone.

    In plain wordsIn patients with vertebral fractures, collagen breakdown marker levels were similar with combined stem-cell-teriparatide treatment and teriparatide alone.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeC-terminal telopeptide of type 1 collagen
    Study

    n = 14

    Comparator
    teriparatide alone
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    (c) the level of bone turnover markers were not significantly different between the two groups;
    2 context sentences
    Summary · context
    Fourteen subjects (teriparatide alone, n = 7; combined treatment, n = 7) completed follow-up assessment (visual analog scale [VAS], Oswestry Disability Index [ODI], Short Form-36 [SF-36], bone mineral density [BMD], bone turnover measured by osteocalcin and C-terminal telopeptide of type 1 collagen,…
    Summary · context
    We conducted a randomized, open-label, phase I/IIa study to determine the feasibility, safety, and effectiveness of Wharton's jelly-derived mesenchymal stem cells (WJ-MSCs) and teriparatide (parathyroid hormone 1-34) in OVCFs.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  5. 05HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialSafety outcome

    In patients with osteoporotic vertebral fractures, combined WJ-MSCs and teriparatide treatment was feasible and tolerable.

    In plain wordsIn patients with osteoporotic vertebral fractures, combined stem-cell and teriparatide treatment was feasible and tolerable.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    Not applicableCombination tolerability
    Study

    n = 7

    Outcome group
    Adverse events · Musculoskeletal

    Source sentences

    Summary
    Our results show that (a) combined treatment with WJ-MSCs and teriparatide is feasible and tolerable for the patients with OVCFs;
    1 context sentence
    Summary · context
    We conducted a randomized, open-label, phase I/IIa study to determine the feasibility, safety, and effectiveness of Wharton's jelly-derived mesenchymal stem cells (WJ-MSCs) and teriparatide (parathyroid hormone 1-34) in OVCFs.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  6. 06HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome

    In patients with osteoporotic vertebral fractures, VAS scores improved significantly in the combined WJ-MSCs and teriparatide group.

    In plain wordsIn patients with osteoporotic vertebral fractures, pain scores improved from baseline with combined stem-cell and teriparatide treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseVAS pain score
    Study

    n = 7

    Comparator
    baseline
    Outcome group
    Pain · Musculoskeletal

    Source sentences

    Summary
    (b) the mean VAS, ODI, and SF-36 scores significantly improved in the combined treatment group;
    1 context sentence
    Summary · context
    We conducted a randomized, open-label, phase I/IIa study to determine the feasibility, safety, and effectiveness of Wharton's jelly-derived mesenchymal stem cells (WJ-MSCs) and teriparatide (parathyroid hormone 1-34) in OVCFs.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  7. 07HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome

    In patients with osteoporotic vertebral fractures, ODI scores improved significantly in the combined WJ-MSCs and teriparatide group.

    In plain wordsIn patients with osteoporotic vertebral fractures, disability scores improved from baseline with combined stem-cell and teriparatide treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseOswestry Disability Index
    Study

    n = 7

    Comparator
    baseline
    Outcome group
    Exercise and physical function · Musculoskeletal

    Source sentences

    Summary
    (b) the mean VAS, ODI, and SF-36 scores significantly improved in the combined treatment group;
    1 context sentence
    Summary · context
    We conducted a randomized, open-label, phase I/IIa study to determine the feasibility, safety, and effectiveness of Wharton's jelly-derived mesenchymal stem cells (WJ-MSCs) and teriparatide (parathyroid hormone 1-34) in OVCFs.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  8. 08HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome

    In patients with osteoporotic vertebral fractures, SF-36 scores improved significantly in the combined WJ-MSCs and teriparatide group.

    In plain wordsIn patients with osteoporotic vertebral fractures, health scores improved from baseline with combined stem-cell and teriparatide treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseSF-36 score
    Study

    n = 7

    Comparator
    baseline
    Outcome group
    Quality of life · Whole body

    Source sentences

    Summary
    (b) the mean VAS, ODI, and SF-36 scores significantly improved in the combined treatment group;
    1 context sentence
    Summary · context
    We conducted a randomized, open-label, phase I/IIa study to determine the feasibility, safety, and effectiveness of Wharton's jelly-derived mesenchymal stem cells (WJ-MSCs) and teriparatide (parathyroid hormone 1-34) in OVCFs.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  9. 09HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome

    In patients with osteoporotic vertebral fractures, follow-up CT images showed better microarchitecture in the combined WJ-MSCs and teriparatide group.

    In plain wordsIn patients with osteoporotic vertebral fractures, follow-up scans showed better bone structure in the combined stem-cell and teriparatide group.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseSpine bone microarchitecture
    Study

    n = 7

    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    (e) baseline spine CT images and follow-up CT images at 6 and 12 months showed better microarchitecture in the combined treatment group.
    1 context sentence
    Summary · context
    We conducted a randomized, open-label, phase I/IIa study to determine the feasibility, safety, and effectiveness of Wharton's jelly-derived mesenchymal stem cells (WJ-MSCs) and teriparatide (parathyroid hormone 1-34) in OVCFs.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.